Loading clinical trials...
Loading clinical trials...
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
Conditions
Interventions
Crofelemer 125 MG [Mytesi]
Placebo
Locations
52
United States
Arizona Oncology Associates PC - HAL
Prescott, Arizona, United States
Pacific Cancer Medical Center Inc
Anaheim, California, United States
The Oncology Institute of Hope and Innovation
Corona, California, United States
The Oncology Institute of Hope and Innovation
Glendale, California, United States
PIH Health Whittier Hospital
Whittier, California, United States
SCL Health Research Institute
Lafayette, Colorado, United States
Start Date
October 7, 2020
Primary Completion Date
August 7, 2023
Completion Date
October 30, 2023
Last Updated
July 26, 2024
NCT07098988
NCT06403436
NCT01137825
NCT06059547
NCT02293954
NCT00483366
Lead Sponsor
Napo Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions